Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
about
Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitorsMeta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapySomatic Mutations in Prostate Cancer: Closer to Personalized Medicine.The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.EGFR T790M: revealing the secrets of a gatekeeper.Features of reactive cysteines discovered through computation: from kinase inhibition to enrichment around protein degrons.Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer.Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer.The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor.Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.EGFR-TKI-induced HSP70 degradation and BER suppression facilitate the occurrence of the EGFR T790 M resistant mutation in lung cancer cells.Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer.The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis.WWC3 inhibits epithelial-mesenchymal transition of lung cancer by activating Hippo-YAP signaling.Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancerArsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer
P2860
Q33553528-FEA5E595-39A1-454B-A77B-FDB0B8E0783FQ33621143-8E78FAC0-369E-4EB1-880A-727894487579Q33859476-C6BD3F44-F084-42C1-BCFC-29D5C5218B0AQ38598893-F5BCDCC4-5395-49D1-9DA7-B9398E6EAAF1Q39044222-ABB5C259-F946-4F92-990E-E147B453E8C2Q42643276-C262B9B8-D02F-46D6-8DA4-E3CC2008EDB5Q42701535-899179DC-1791-47CF-A444-538A1DE2E245Q47093526-068B656B-059E-40D0-8BEB-AB5741B28566Q47100541-B4F7FB4F-8E9D-4B77-881A-9E99556053CAQ47102325-5E7D4E46-D275-4C88-A249-32A1C6351879Q47115593-E71A8EBB-96B7-4BE4-9CE1-61EBDEE327ADQ47153925-FC3F7F56-C61E-4F62-B3A5-1F6A8FA4D614Q47157402-4CD4EFEF-24FF-4324-B806-22832EB737FCQ49643911-FE713EDA-054B-451C-8B95-05853766F7ABQ49887919-114C79D0-0576-44C4-99E6-9C257C9EA4B3Q51741893-BBBF7EE8-9B04-44A9-90ED-4F3DB19DE1B4Q54113349-5BCCAFBF-AFAA-45DE-8C5E-BE1C815497C5Q55044764-EEB60287-F901-4B39-842B-D521D24FE9F9Q55393865-887EEE24-F5B0-495D-8444-15F5DF9EB23CQ57736167-340F4E72-2A92-4FD3-8F6D-265BDC1B5CEEQ58712613-104120D5-5F07-424B-A476-F20C466D4E97
P2860
Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
@en
type
label
Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
@en
prefLabel
Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
@en
P2093
P2860
P1476
Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
@en
P2093
Delong Liu
Feifei Yan
Shuhang Wang
Yongping Song
P2860
P2888
P304
P356
10.1007/S11684-016-0488-1
P577
2016-10-21T00:00:00Z
P6179
1011487387